The nutraceutical and pharmaceutical sectors are moving away from vague marketing claims and toward solid clinical evidence. At CPHI Milan 2026, firms will display ingredients supported by rigorous human studies—ranging from hair health to heart function—while being transparent about exactly what the science confirms. This shift mirrors heightened regulatory attention and a growing consumer appetite for proof.
The firm’s broader ambition, however, is to back its entire portfolio with peer-reviewed data. In the same vein, the saffron-derived ingredient Affron recently released results from a study involving women aged 50–70, indicating improvements in mood, sleep quality, and self-esteem; but only within that specific age group.
His comments highlight the increasing demand for factual backing rather than aspirational language.
This drive for precision extends to ProBiotix Health, which is deepening its focus on the connection between gut microbes and cardiometabolic health. Its patented strain LPLDL has undergone several human trials that demonstrated favorable effects on cholesterol levels, triglycerides, and blood pressure.
Meanwhile, Fuji Chemical Industries is tackling a rising concern: digital eye strain among children. Research conducted in India showed that AstaReal Natural Astaxanthin reduced both chronic and acute screen-related fatigue in participants aged 10–14. The firm is also positioning astaxanthin within a wider “health span” approach, emphasizing support for functional abilities throughout a person’s life rather than focusing solely on longevity.
ThreoTech is following a similar path with its patented magnesium L-threonate, marketed as Magtein.
The emphasis on clinical rigor is not limited to active compounds. Natix plans to exhibit enzyme solutions designed for digestive and skin health, while Wecare Probiotics will present strains such as BLa80, which have been validated in more than twenty trials for infant nutrition and immune support. Even suppliers of excipients, Lubrizol and Gelita, are showcasing technologies like rapid-release softgels and endotoxin-controlled materials intended for vaccine formulations.
At the same time, firms are wrestling with how to convey findings accurately. This careful stance reflects a broader industry movement where hype is giving way to measurable outcomes.
Medical Device Certification and Supplier Showcases at CPHI Milan
AB-Biotics’ Gyntima Restore postbiotic medical device for vaginal health has received Medical Devices Directive certification. The certification confirms compliance with EU safety and performance standards for medical devices.
Univar Solutions will showcase its ingredients, formulation expertise, and market insights, concentrating on API sourcing, excipients, biopharma ingredients, GLP-1 solutions, and high-purity solvents. These capabilities aim to support the development of next-generation pharmaceutical and nutraceutical products.
Lubrizol will focus on multifunctional excipients and drug-delivery solutions to improve product performance while meeting patient needs. Sirio Europe will present nutraceutical innovations such as LifeChews jelly tablets, FizzyBits fizzy tabs, and creatine gummy flavors. Offerings include pharma-grade omega-3 softgels, the Aeion longevity platform, and a preview of Snowmelt, a mouth powder format.
